Overview

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this research study is to find out if de-escalation of chemotherapy before surgery followed by a selective escalation of adjuvant targeted therapies are efficacious and tolerable in early-stage HER2 positive breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
University of Rochester
Treatments:
Ado-Trastuzumab Emtansine
Carboplatin
Docetaxel
Maytansine
Pertuzumab
Trastuzumab